	US 11,813,356 B2
	Dosing regimens for treatment of proliferative disorders
Peter Sordillo, New York, NY (US)
Assigned to Signpath Pharma, Inc., Sandy, UT (US)
Appl. No. 17/045,431
Filed by Signpath Pharma, Inc., Sandy, UT (US)
PCT Filed Mar. 28, 2019, PCT No. PCT/US2019/024495 § 371(c)(1), (2) Date Oct. 5, 2020, PCT Pub. No. WO2019/199469, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/655,095, filed on Apr. 9, 2018.
Prior Publication US 2021/0161815 A1, Jun. 3, 2021
Int. Cl. A61K 9/127 (2006.01); A61P 35/04 (2006.01); A61K 9/00 (2006.01); A61K 31/12 (2006.01); A61K 45/06 (2006.01)

CPC A61K 9/127 (2013.01) [A61K 9/0019 (2013.01); A61K 31/12 (2013.01); A61K 45/06 (2013.01); A61P 35/04 (2018.01)]

10 Claims

1. A method of treating a proliferative disorder comprising administering a therapeutically effective amount of an intravenous liposomal curcumin or curcuminoids to a human subject in need thereof in accordance with a dosing regimen comprising: at least one treatment cycle administering the therapeutically effective amount of the liposomal curcumin or curcuminoids of at least 125 mg/m²over 3, 4, 5, 6, 7, or 8 hours or less, wherein the treatment cycle is followed by a rest period of 4, 5, 6, or 7 days during which no liposomes or active agent are administered, and wherein the treatment cycle is repeated for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 consectuive weeks.